EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre

Anna-Maria Lazaratos iD, Matthew Dankner iD, Aalya Hamouda, Soumaya Labidi, Victor Cohen, Lawrence Panasci, Jennifer E Friedmann, François Patenaude, Cristiano Ferrario, Mark Basik iD, April A N Rose, Parvaneh Fallah

Current Oncology · 24.12.2024 · 32 (1) · 1

DOI: 10.3390/curroncol32010001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, online erschienen am 24.12.2024. Verfasst von Anna-Maria Lazaratos und 11 weiteren Autor:innen. Beteiligte Einrichtung: Rosalind and Morris Goodman Cancer Institute, Montreal, QC H3A 1A3, Canada. Hauptthemen laut MEDLINE: Breast Neoplasms, Trastuzumab, Erb-b2 Receptor Tyrosine Kinases, Immunoconjugates. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Trastuzumab deruxtecan (TDXd) is an antibody–drug conjugate that has demonstrated impressive activity in randomized controlled clinical trials in the context of patients with HER2-amplified and HER2-low metastatic breast cancer. We aimed to review the activity and adverse event profile of TDXd in heavily pretreated breast cancer patients in real practice.

Methods

We describe a single-center retrospective case series of metastatic breast cancer patients who were treated with TDXd. The outcomes of interest were the overall response rate, overall survival, progression-free survival and grade 4–5 adverse events. Objective responses and PFS were assessed in accordance with RECIST 1.1 criteria.

Results

We identified 38 patients treated with TDXd. Of these, 15 patients had classically defined HER2-positive (HER2+) breast cancer, 4 of whom had active central nervous system (CNS) metastases. A total of 23 patients had HER2-low breast cancer, 2 of whom had active CNS disease. Of the 33 patients evaluable for response, 21 (63%) patients had a response to treatment, including three (9%) complete responses. Outcomes were similar between patients with a HER2+ and HER2-low status, as well as in patients with or without CNS metastases. No patients experienced grade 4 or 5 toxicities, and four of thirty-eight patients (10.5%) experienced pneumonitis (two patients with grade 3 pneumonitis, one patient with grade 2 and one patient with grade 1), resulting in TDXd discontinuation for three patients (with steroid administration in two patients).

Conclusions

TDXd demonstrates impressive activity with manageable adverse event profiles in this heavily pretreated population that includes patients with active CNS metastases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsTrastuzumabErb-b2 Receptor Tyrosine KinasesImmunoconjugatesCamptothecinAntineoplastic Agents, ImmunologicalHumansFemaleMiddle AgedRetrospective StudiesAdultAgedNeoplasm MetastasisTreatment Outcome

Stichwörter der Autor:innen

TDXdantibody–drug conjugatebreast cancerderuxtecantrastuzumab

Substanzen

TrastuzumabErb-b2 Receptor Tyrosine KinasesImmunoconjugatesCamptothecinAntineoplastic Agents, Immunologicaltrastuzumab deruxtecanERBB2 protein, human

Autor:innen und Institutionen

  • Rosalind and Morris Goodman Cancer Institute, Montreal, QC H3A 1A3, Canada.
  • Faculty of Medicine, McGill University, Montreal, QC H3G 2M1, Canada.
  • Jewish General Hospital, Montreal, QC H3T 1E2, Canada.

ORCID-Profile: Anna-Maria Lazaratos, Matthew Dankner, Mark Basik

Zitieren

APA

Lazaratos, A. M., Dankner, M., Hamouda, A., Labidi, S., Cohen, V., Panasci, L., Friedmann, J. E., Patenaude, F., Ferrario, C., Basik, M., Rose, A. A. N., & Fallah, P. (2024). The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre. Current Oncology, 32(1), 1. https://doi.org/10.3390/curroncol32010001

Vancouver

Lazaratos AM, Dankner M, Hamouda A, Labidi S, Cohen V, Panasci L, et al. The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre. Current Oncology. 2024;32(1):1. doi:10.3390/curroncol32010001

BibTeX
@article{Lazaratos2024,
  author = {Lazaratos, Anna-Maria and Dankner, Matthew and Hamouda, Aalya and Labidi, Soumaya and Cohen, Victor and Panasci, Lawrence and Friedmann, Jennifer E and Patenaude, François and Ferrario, Cristiano and Basik, Mark and Rose, April A N and Fallah, Parvaneh},
  title = {The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre},
  journal = {Current Oncology},
  year = {2024},
  volume = {32},
  number = {1},
  pages = {1},
  doi = {10.3390/curroncol32010001}
}
Kostenlos starten →